Please login to the form below

Not currently logged in
Email:
Password:

FDA warning letter for Aurobindo

India based generics manufacturer, Aurobindo Pharma, has received warning letters from the US Food and Drug Administration calling for changes at two of the company's facilities

India based generics manufacturer, Aurobindo Pharma, has received warning letters from the US Food and Drug Administration (FDA) calling for changes at two of the company's facilities.

In a statement, the company explained that the FDA has requested a 'detailed action plan' for improvements regarding packaging and labelling compliance at unit three of its Hyderabad plant. This was based on a previous field alert report by the agency.

Aurobindo have 15 working days to submit the action plan, with the opportunity to discuss the situation at a regulatory meeting with the FDA.

Aurobindo said it was in the process of responding to these requests.

The FDA also issued an official warning letter following an earlier import alert on Aurobindo's unit six cephalosporin manufacturing plant, which required detention of products from the facility.

23rd May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Article: What's next? How behavioural science can support pharma's future
...
Video: UX/ Experience design research
...

Infographics